Skip to main content
XENE
NASDAQ Life Sciences

Xenon Pharmaceuticals 发起 5 亿美元公开募股，随着第三期试验数据强劲

feedReported by GlobeNewswire
Sentiment info
Neutral
Importance info
9
Price
$62.25
Mkt Cap
$5.221B
52W Low
$26.74
52W High
$62.915
Market data snapshot near publication time

summarizeSummary

Xenon Pharmaceuticals 宣布启动以承销方式进行的公开募股，计划出售其 5 亿美元的普通股，承销商拥有购买额外 7500 万美元的选项。这一重大资本募集，潜在总额为 5.75 亿美元，在今天早些时候宣布的第三期 X-TOLE2 研究高度积极的顶线结果之后进行，可能推动股票价格接近其 52 周高位。虽然此次募股为公司专注于神经系统的药物开发提供了大量资金，但这代表了对现有股东的重大稀释，约占当前市值的 10-11%。此次募股的时机表明这是一个机会主义举动，旨在利用股票价值在临床试验成功后的有利定价。交易者将密切关注此次募股的定价及其对股价的即时影响。

在该公告发布时，XENE的交易价格为$62.25，交易所为NASDAQ，所属行业为Life Sciences，市值约为$52.2亿。 52周交易区间为$26.74至$62.91。 这则新闻被评估为中性市场情绪，重要性评分为9/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed XENE - Latest Insights

XENE
Apr 22, 2026, 4:02 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Shareholders to Vote on New 2026 Equity Incentive Plan Authorizing up to 7.5M Shares
Sentiment: Neutral
View Wiseek Article
XENE
Mar 12, 2026, 4:23 PM EDT
Source: Wiseek News
Importance Score:
8
Xenon Pharmaceuticals Closes Upsized Offering, Nets $707.7M
Sentiment: Neutral
View Wiseek Article
XENE
Mar 12, 2026, 4:17 PM EDT
Filing Type: 8-K
Importance Score:
9
Xenon Pharmaceuticals Closes Upsized $707.7M Public Offering Following Positive Phase 3 Results
Sentiment: Positive
View Wiseek Article
XENE
Mar 11, 2026, 5:47 PM EDT
Filing Type: 424B5
Importance Score:
9
Xenon Pharmaceuticals Finalizes Upsized $650M Public Offering at Premium Price Following Positive Phase 3 Data
Sentiment: Positive
View Wiseek Article
XENE
Mar 10, 2026, 10:41 PM EDT
Source: Reuters
Importance Score:
8
Xenon Pharma Prices Upsized $650M Offering at $57.00 Per Share
Sentiment: Negative
View Wiseek Article
XENE
Mar 10, 2026, 9:23 PM EDT
Filing Type: FWP
Importance Score:
7
Xenon Pharmaceuticals Adds Pre-Funded Warrants to $500M Public Offering
Sentiment: Neutral
View Wiseek Article
XENE
Mar 09, 2026, 4:54 PM EDT
Filing Type: 424B5
Importance Score:
9
Xenon Pharmaceuticals Launches $500M Underwritten Offering at Pre-News Price Following Positive Phase 3 Data
Sentiment: Neutral
View Wiseek Article
XENE
Mar 09, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
9
Xenon Pharmaceuticals Launches $500M Public Offering Following Strong Phase 3 Data
Sentiment: Neutral
View Wiseek Article
XENE
Mar 09, 2026, 7:36 AM EDT
Filing Type: 8-K
Importance Score:
9
Xenon's Azetukalner Phase 3 Study Exceeds Expectations with Record Efficacy in Focal Onset Seizures
Sentiment: Positive
View Wiseek Article
XENE
Mar 09, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Xenon's Azetukalner Delivers 'Highest Efficacy Ever' in Phase 3 Epilepsy Study, NDA Submission Planned
Sentiment: Positive
View Wiseek Article